NIH trial success suggests a new treatment option for older, sicker patients. Half of patients in a trial have safely stopped immunosuppressant medication following a modified blood stem-cell transplant for severe sickle cell disease, according to a study in the July 1 issue of the Journal of the American Medical Association External Web Site Policy. The trial was conducted at the National Institutes of Health’s Clinical Center in Bethesda, Maryland, by researchers from NIH’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Heart, Lung, and Blood Institute.
Related posts:
- Medicare, Gene Pattern, May Identify Kidney Transplant Recipients, Who Don’t Need Life-long Anti-rejection Drugs Researchers have identified a distinct pattern of gene expression in the largest reported group of kidney transplant recipients who have not rejected the transplant kidneys even though they stopped taking anti-rejection drugs. This finding may help identify other transplant recipients who could safely reduce or end use of immunosuppressive therapy. In 2008, more than 80,000 […]...
- Medicare Card, NIH launches largest clinical trial focused on HIV-related cardiovascular disease Medicare Card, NIH launches largest clinical trial focused on HIV-related cardiovascular disease...
- Medicare Card, Therapy with bone marrow-derived stem cells does not improve short-term recovery after heart attack Medicare Card, Therapy with bone marrow-derived stem cells does not improve short-term recovery after heart attack...
- Medicare NIH to host sickle cell disease symposium More than 30 experts from around the world are scheduled to present Nov. 16-17 in Bethesda, Md., at the James B. Herrick Symposium — Sickle Cell Disease Care and Research: Past, Present, and Future. The free event, hosted by the National Institutes of Health, will examine the past century of work toward understanding sickle cell […]...
- Medicare Card, Age-related macular degeneration before and after the era of anti-VEGF drugs Medicare Card, Age-related macular degeneration before and after the era of anti-VEGF drugs...
- Medicare Card, Stroke Prevention Study, Children with Sickle Cell Anemia, Iron Overload Stopped Early The National Heart, Lung, and Blood Institute (NHLBI) has stopped a clinical trial evaluating a new approach to reduce the risk of recurrent stroke in children with sickle cell anemia and iron overload because of evidence that the new treatment was unlikely to prove better than the existing treatment....
- Medicare Card, Monthly blood transfusions reduce sickle cell anemia-related brain injury in children Medicare Card, Monthly blood transfusions reduce sickle cell anemia-related brain injury in children...
- Medicare Card, Drugs that activate brain stem cells may reverse multiple sclerosis Medicare Card, Drugs that activate brain stem cells may reverse multiple sclerosis...
- Medicare Card, Stem cell transplants may halt progression of multiple sclerosis Medicare Card, Stem cell transplants may halt progression of multiple sclerosis...
- Medicare, NHLBI to Hold Workshop, Health Consequences of Sickle Cell Trait Scientists from across the nation will gather June 3-4 to discuss what is known about sickle cell trait and the potential health implications related to this genetic blood condition. “Framing the Research Agenda for Sickle Cell Trait” will examine the ethical, legal, social, and public health impacts of the blood condition....
- Method to improve transplant cell delivery A new technique for improving delivery of stem cells may lead to better and faster tissue repair, a breakthrough with promise for sports medicine and military populations....
- Medicare: Cholesterol levels elevated in toddlers taking anti-HIV drugs Toddlers receiving anti-HIV drugs have higher cholesterol levels, on average, than do their peers who do not have HIV, according to researchers at the National Institutes of Health and other institutions....
- Medicare Card, Suppressing protein may stem Alzheimer’s disease process Medicare Card, Suppressing protein may stem Alzheimer's disease process...
- Medicare Card, Suppressing Protein May Stem Alzheimer’s Disease Process Medicare Card, Suppressing Protein May Stem Alzheimer’s Disease Process...
- Delayed stem cell therapy following heart attack is safe but not effective Stem cells obtained from bone marrow, known as BMCs, can be safely injected into people 2-3 weeks following a heart attack, reports a new clinical trial supported by the National, Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health. However, while safe, the BMCs did not improve heart function six months […]...